1. Chen, Yueda, Ye, Botian, Wang, Chunyan, Qin, Jing, Shen, Zhenbin. 2022. PLOD3 contributes to HER-2 therapy resistance in gastric cancer through FoxO3/Survivin pathway. In Cell death discovery, 8, 321. doi:10.1038/s41420-022-01103-4. https://pubmed.ncbi.nlm.nih.gov/35835735/
2. Ewans, Lisa Jean, Colley, Alison, Gaston-Massuet, Carles, Buckley, Michael, Roscioli, Tony. 2019. Pathogenic variants in PLOD3 result in a Stickler syndrome-like connective tissue disorder with vascular complications. In Journal of medical genetics, 56, 629-638. doi:10.1136/jmedgenet-2019-106019. https://pubmed.ncbi.nlm.nih.gov/31129566/
3. Baek, Jeong-Hwa, Yun, Hong Shik, Kwon, Gyoo Taik, Kim, Eun Ho, Hwang, Sang-Gu. 2018. PLOD3 promotes lung metastasis via regulation of STAT3. In Cell death & disease, 9, 1138. doi:10.1038/s41419-018-1186-5. https://pubmed.ncbi.nlm.nih.gov/30442941/
4. Shi, Junhong, Bao, Meiyu, Wang, Weifeng, Zhao, Changdong, Liu, Weiwei. 2021. Integrated Profiling Identifies PLOD3 as a Potential Prognostic and Immunotherapy Relevant Biomarker in Colorectal Cancer. In Frontiers in immunology, 12, 722807. doi:10.3389/fimmu.2021.722807. https://pubmed.ncbi.nlm.nih.gov/34646265/
5. Guo, Xing, Hu, Wenjun, Gao, Zijie, Wu, Qianqian, Li, Weiguo. 2023. Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson's disease based on integrative analysis. In NPJ Parkinson's disease, 9, 82. doi:10.1038/s41531-023-00527-8. https://pubmed.ncbi.nlm.nih.gov/37258507/
智鼠故事 
